| TIME |
PROGRAM |
 |
| 8:30 - 8:45 |
Welcome Address |
|
| |
Ambassador of France, HR Pierre Vimont |
| 8:45 - 9:00 |
Welcome and Introductions |
| |
Prof. J.H Growdon, Clinical Core Co-Leader and Founding Director at Massachusetts Alzheimer's Disease Research Center & Director, Memory and Movement Disorders Units at Massachusetts General Hospital & Professor of Neurology at Harvard Medical School
Prof. P. Amouyel, CEO French National Foundation on AD, General Director of the Pasteur Institute of Lille and Professor of Epidemiology and Public Health at the University Hospital of Lille in France. |
| 9am-9.30am |
Session I : New Genes for New Clues |
| |
Prof. Philippe Amouyel
Topic: European Alzheimer's Disease Initiative Consortium (EADI), a European GWAS
Dr. Sudha Seshadri
Topic: Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) and Alzheimer’s disease |
|
| 9.30-10am |
Panel discussion |
| 10-10:30am |
Session II : New Molecular Vision of AD |
| |
Prof. Bradley Hyman
Topic: soluble Aß and synaptic damage in AD
Dr. Frederic Checler
Topic: Aß and tau neurotoxicity |
|
| 10.30–11am |
Panel discussion |
| 11-11.30.am |
Coffee break |
| 11.30-12:15 |
Session III : Prodromal AD - New Diagnostic Challenges |
 |
Prof. Guy McKhann
Topic: National Institute of Ageing update on AD diagnostic criteria
Prof. Bruno Dubois
Topic: Revised diagnostic guidelines for the MCI-AD continuum
Dr. Deborah Blacker
Topic: DSM-V criteria for dementia and AD |
|
| 12:15-12:45 pm |
Panel discussion |
| 12:45-2:00 pm |
Lunch |
| 2:00 – 2:30 pm |
Session IV : New ways to Image the AD brain |
| |
Prof. Chester Mathis
Topic: Brain amyloid imaging and its impact on AD research
Dr. Stephane Lehericy
Topic: MRI techniques to diagnose and chart the course of AD |
|
| 2.30 – 3:00 pm |
Panel discussion |
| 3:00 – 3:30 pm |
Coffee break |
| 3:30 – 4:00 pm |
Session V : New Therapeutics for AD |
| |
Dr. Reisa Sperling
Topic: Incorporating biomarkers (CSF, neuroimaging) into clinical AD trials
Prof. Jean-Marc Orgogozo
Topic: Perspectives for developing novel symptomatic and neuroprotective drugs for AD |
|
| 4:00 – 4:30 pm |
Panel discussion with Speakers |
| |
Session VI : Biopharmaceutical perspectives & the drug market |
| 4:30-5:00 pm |
Dr. Dana Hilt, Chief Medical Officer of Envivo at Envivo Pharmaceutical
Topic: “Symptomatic Versus Disease Modification Treatments for Alzheimer’s Disease from the Perspective of a CNS Biotech Company”
French biopharmaceutical company: Subject to minor changes |
| 5:00 pm |
Concluding remarks: Profs. Growdon and Amouyel |
|
|
